Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. L. Bedrosian

Development of a Pharmacokinetic (PK) Model and Assessment of Patient (Pt) Covariate Effects on Dose-Dependent PK Following Different Dosing Schedules in Two Phase I Trials of AP23573 (AP), a mTOR Inhibitor

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

Escherichia Coli Replication Terminator Protein Impedes Simian Virus 40 (SV40) DNA Replication Fork Movement and SV40 Large Tumor Antigen Helicase Activity in Vitro at a Prokaryotic Terminus Sequence.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1991English

Related publications

First-In-Human Phase I Study of a Dual mTOR Kinase and DNA-PK Inhibitor (CC-115) in Advanced Malignancy

Cancer Management and Research
Oncology
2019English

Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: A Step Toward Model-Based Dose Optimization

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2011English

Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Anti-Neoplastic Agents

2012English

In House Training Pada Perawat PK I-Pk IV Terhadap Pengetahuan Tentang Manajemen Nyeri

Klabat Journal of Nursing
2019English

Population Pharmacokinetic Assessment of Vancomycin Dosing in the Large Pediatric Patient

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2019English

The Pharmacokinetic (PK) Interaction Between Omeprazole and TMC278, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)

Journal of the International AIDS Society
EnvironmentalPublic HealthInfectious DiseasesOccupational Health
2008English

A Phase I Trial and PK Study of Cediranib (AZD2171), an Orally Bioavailable Pan-Vegfr Inhibitor, in Children With Recurrent or Refractory Primary CNS Tumors

Child's Nervous System
MedicineChild HealthNeurologyPediatricsPerinatology
2015English

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Dalbavancin Alone and in Combination With Ceftaroline Against Four Different Phenotypes of Staphylococcus Aureus in a PK/PD Model

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy